MinorAntiepileptics (other)×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
Levetiracetam is not extensively metabolised and is cleared by the kidneys. Its primary metabolite is formed without cytochrome P450 enzymes, and levetiracetam does not inhibit these enzymes (Keppra SmPC, European Medicines Agency, EMA, section 5.2). Phenytoin is metabolised in the liver mainly by CYP2C9 and to a lesser extent by CYP2C19 (Epanutin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). In clinical studies in adults, levetiracetam did not change serum phenytoin concentrations and phenytoin did not change levetiracetam pharmacokinetics. In children, enzyme-inducing antiepileptics may increase levetiracetam clearance by about 20%, but no dose adjustment is needed (Keppra SmPC, EMA, section 4.5).
Symptoms
The documents describe no symptoms caused by this combination. Suicidal thoughts and behaviour have been reported with antiepileptic drugs, including levetiracetam and phenytoin, and patients are monitored for these signs (Keppra SmPC, European Medicines Agency, EMA, section 4.4; Epanutin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). High serum phenytoin levels cause signs of toxicity, and megaloblastic anaemia has been reported with phenytoin (Epanutin SmPC, AEMPS, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of levetiracetam or phenytoin is needed. In studies, neither drug affected the concentrations of the other (Keppra SmPC, European Medicines Agency, EMA, section 4.5). If serum phenytoin levels are high, the phenytoin dose is reduced, and phenytoin is stopped if symptoms persist (Epanutin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Levetiracetam clearance correlates with creatinine clearance, so in renal impairment its dose is adjusted accordingly (Keppra SmPC, EMA, section 5.2).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- EMA: Ficha técnica: Levetiracetam (EU/1/00/146), sección 4.5 (2026)– EMA, Keppra 500 mg comprimidos recubiertos con película (UCB Pharma, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 00146010, consultada 29.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5 y 5.2